Drug (Brand / Generic)
Lovenox / enoxaparin sodium
Lovenox (enoxaparin sodium) is an anti-thrombotic drug indicated for the treatment of deep vein thrombosis (DVT), ischemic complications of unstable angina and acute ST-segment elevation myocardial infarction (STEMI).
Lovenox was developed and manufactured by Rhone Poulenc Rorer, who merged with Sanofi-Aventis in 2004. Approval from the US Food and Drug Administration (FDA) was received in February 1998 for treating DVT and in 2007 for the treatment of STEMI.
In July 2010, Momenta Pharmaceuticals, in partnership with Sandoz, received approval from the US Food and Drug Administration for the first generic version of lovenox.
Deep vein thrombosis is a blood clot that forms in a vein, generally occurring in the lower leg or thigh, but DVT can also occur in other parts of the body. It occurs when blood thickens and clumps together.
Signs of the disease include swelling, pain, warmness, redness and engorged superficial veins in the leg. DVT affects about one in 1,000 adults.
Lovenox is a blood thinner containing a low molecular weight heparin. The drug binds and accelerates the activity of antithrombin III, an enzyme which causes blood to clot by acting on a blood protein called fibrinogen.
It also inhibits coagulation factors Xa and IIa. The drug is an anticoagulant and prevents conversion of prothrombin into thrombin and stops formation of fibrin clot.
It is administered intravenously and is available in 100mg / ml and 150mg / ml doses.
Lovenox was approved by the FDA for the extended prevention of deep-vein thrombosis following hip replacement surgery, in February 1998.
The FDA approval was based on a Phase III clinical study which enrolled patients discharged from hospitals without signs of venous thromboembolic disease. It compared lovenox with a placebo, by administering either a three-week regimen of lovenox or placebo.
The results of the study showed that the incidence of DVT was significantly lower in lovenox-administered patients (seven percent), when compared to placebo-administered patients (20%).
Sanofi-Aventis conducted Phase II / Phase III clinical trials on lovenox from July 2008 to May 2009. It was a multinational, multicentre, randomised double-blind study which evaluated the efficacy and safety of enoxaparin sodium for the prevention of venous thromboembolism following hip replacement surgery. The study enrolled 1,150 patients.
The primary outcome measure was to find the occurrence of the composite endpoint of any VTE. Secondary endpoints included finding the composite endpoint of any proximal deep vein thrombosis and the number of patients requiring the initiation of curative anticoagulant or thrombolytic treatment.
Sanofi-Aventis also conducted a Phase III clinical trial known as ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment, Thrombolysis In Myocardial Infarction – 25 Study) on lovenox between October 2002 and December 2006. It was a multicentre, randomised, double-blind and parallel assignment, enrolling 20,506 patients with ST-segment elevation acute myocardial infarction.
The primary outcome measure of the study was finding the composite of all-cause mortality and non-fatal myocardial re-infarction. The secondary outcome measures included finding myocardial ischemia leading to urgent revascularisation and non-fatal disabling stroke.
The study results were announced in April 2006, and in May 2007 the FDA also approved the drug for the treatment of patients with STEMI.
Results demonstrated that enoxaparin significantly reduced the rate of death or recurrent infarction at 30 days by 17% when compared to unfractionated heparin (UFH). It also found that the rate of bleeding in enoxaparin group at 30 days was 2.1%, compared to 1.4% in the UFH group.
Plavix (clopidogrel bisulfate) is a thienopyridine class inhibitor indicated for the treatment of acute coronary syndrome (ACS).
Lovenox is the second best-selling drug from Sanofi-Aventis. With FDA approval of generic lovenox in 2010, Sanofi-Aventis has been facing severe competition from generic manufacturers of the drug.
In 2010, the company received $4.28bn in revenue through the global sales of lovenox. The drug’s sales, however, dropped to $1.5bn during the first half of 2011.
In September 2011, Amphastar and Watson Pharmaceuticals were given approval for the marketing, sale and distribution of generic lovenox in the US.
Brukinsa® (zanubrutinib) is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor indicated for the treatment of Waldenstrom’s macroglobulinaemia (WM) and…
Soliris (eculizumab) is a drug indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS), generalised…
Tazverik (tazemetostat) is a methyltransferase inhibitor of EZH2 indicated for the treatment of patients with epithelioid sarcoma and certain patients…
Korsuva™ (difelikefalin) is a first-in-class treatment option indicated for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults on…